Corrigendum to ‘Brief Report: Clinical Outcomes by Infusion Timing of Immune Checkpoint Inhibitors in Patients With Locally Advanced NSCLC’ [JTO Clinical and Research Reports, Volume 5 Issue 4 (2024) 100659]

• Tsuyoshi Hirata, MD,
• Yuji Uehara, MD,
• Taiki Hakozaki, MD,
• Takayuki Kobayashi, MD,
• Yuto Terashima, MD,
• Kageaki Watanabe, MD,
• Makiko Yomota, MD, PhD,
• Yukio Hosomi, MD, PhD

Affiliations

Tsuyoshi Hirata, MD

Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan

Yuji Uehara, MD

Department of Precision Cancer Medicine, Center for Innovative Cancer Treatment, Tokyo Medical and Dental University, Tokyo, Japan; Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan; Corresponding author: Yuji Uehara.

Taiki Hakozaki, MD

Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan

Takayuki Kobayashi, MD

Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan

Yuto Terashima, MD

Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan; Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan

Kageaki Watanabe, MD

Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan

Makiko Yomota, MD, PhD

Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan

Yukio Hosomi, MD, PhD

Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan